Clinical Trial Update: Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial evaluating GSK1265744 with NRTIs for induction and maintenance of HIV-1 virologic suppression; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• GSK1265744 (dolutegravir? wait: GSK1265744 is cabotegravir)
• rilpivirine (rilpivirine)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus, HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2020-01-30